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and/or high altitude cerebral edema (HACE) (Basnyat, 2001; Hackett and Roach, 2001) . The best method of AMS prevention remains a slow, conservative ascent to altitude, with minimal physical exertion in order to acclimatize. However, this is sometimes impractical, such as with AMS-susceptible persons attempting to go to high altitude and rescue or military endeavors. It therefore becomes important to take additional prophylactic measures to reduce the incidence of AMS in these at-risk groups, thereby also decreasing the incidence of HAPE and HACE.
Acetazolamide is a carbonic anhydrase inhibitor that acts as a diuretic and induces mild metabolic acidosis with a concomitant reflex hyperventilation. Acetazolamide is the most studied and current "gold standard" pharmacologic intervention for altitude sickness; however, the optimum prophylactic dose of this medication has not been well established (Reid et al., 1994; Basnyat, 2001) . While most studies using acetazolamide as AMS prophylaxis employed 500 mg per day (Grissom et al., 1992) or higher, only one anecdotal report with nine subjects has employed a lower dose of 250 mg per day in an attempt to find the lowest possible dose (Mayer, 1995) . In 2000, a controversial meta-analysis authored by Dumont et al. stated that 750 mg of acetazolamide was the ideal dose, and a lesser dosage was not effective for the prevention of AMS (Dumont et al., 2000) . Many prominent altitude researchers have criticized Dumont's analysis and suggest that this dosage is unnecessarily high and causes excessive side effects that may lead to poor compliance (Hackett, 2001; Severinghaus, 2001) . Additionally, Dumont's conclusions are contrary to our own observation in the heavily traveled Nepal Himalayas, where for over a decade our regimen of 125 mg BID has been clinically effective in preventing AMS among trekkers. However, this has not yet been adequately demonstrated in a rigorous clinical trial. This study was designed to verify our hypothesis that a prophylactic regimen of acetazolamide 125 mg BID will effectively prevent AMS in Himalayan trekkers. A lower dosage of acetazolamide for prevention of AMS with concomitant fewer side effects (paresthesias, polyuria, occasional nausea and vomiting, drowsiness, and rarely blurring of vision, Hardman et al., 2001 ) is certainly preferable if effective; hence the clinical importance for this study.
METHODS

Protocol
This study was designed as a prospective randomized, double-blind, placebo-controlled trial. The study took place between November 1 and 22, 2001, along the popular trekking route to Mount Everest in the Nepal Himalaya. It was conducted under the auspices of the Himalayan Rescue Association and the Nepal International Clinic and was approved by the Nepal Health Research Council. Study administrators were unpaid upper-level medical students. Preliminary estimates suggested that at minimum 60 subjects per group would be needed in order to resolve a statistically significant difference between treatment and placebo groups based on a published AMS attack rate of 57% at 4950 m (Murdoch, 1995) .
Instruments
The Lake Louise Acute Mountain Sickness Scoring System is a well-validated discipline standard for field evaluation of AMS Roach et al., 1993; Maggiorini et al., 1998) . AMS in a high altitude setting is defined as headache plus at least one of the following symptoms: nausea, fatigue, dizziness, or difficulty sleeping. HACE and HAPE have also been quantified previously by their clinical findings (Roach et al., 1993) . Oxygen saturation is roughly correlated with illness and was measured using a pulse oximeter (Nonin Medical Products Inc., Minneapolis, MN). The measurement was carried out with the person at rest in the evening.
Outcome measures. The main outcome measures were incidence and severity of AMS as judged by the Lake Louise Questionnaire score at Lobuje (4937 m), the study endpoint. Secondary outcome variables included (1) the presence or absence of high altitude headache; (2) diagnosis of HAPE or HACE; (3) pulse oximetry differential between Pheriche (4243 m), the study enrollment site, and Lobuje (4937 m), the study endpoint ( Figs. 1 and 2) ; (4) acute symptoms suggestive of infection at 4937 m (sore throat, cough, sinusitis, diarrhea); (5) incidence of paresthesias; and (6) missed capsules.
Assignment
Participants included 197 trekkers, who received no incentives and gave full consent before participation. Inclusion criteria specified healthy non-Nepali male and female trekkers of greater than 18 years of age traveling between the villages of Pheriche and Lobuje. Potential subjects were excluded if they (1) already had a diagnosis of AMS, HACE, or HAPE; (2) had been on a high altitude trek 2 weeks prior to this trek; (3) were not trekking directly to Lobuje; (4) had taken acetazolamide or Ginkgo biloba in the week prior to presentation; or (5) had diabetes, serious heart or pulmonary disease, or a sulfa allergy.
Masking
This study was conducted as a double-blind trial. Acetazolamide and study capsules were visually indistinguishable, and neither study administrators nor participants knew the identity of any of the study capsules. With the complaint of paresthesias typical for acetazolamide users, there was concern that administrators may become unblinded. To prevent this, subjects were asked to fill in data on side effects last, and their data sheet was promptly sequestered from investigators. Random allocation occurred on site, with each container taken out and assigned to the next person before that person was identified in order to remove bias. Randomization code was drawn up by a neutral party and was securely kept in Kathmandu, completely unavailable to the study administrators.
Participant flow and follow-up
Trekkers newly arrived at Pheriche were enrolled ( Fig. 2) on a daily basis, answering questions concerning demographics and rate of ascent from Lukla (2000 m) (see Table 1 ). Participants filled out the Lake Louise Questionnaire, had pulse oximetry readings taken, and were then randomized in a double-blind fashion to either acetazolamide 125 mg or visually matched placebo twice daily. Participants were then allowed to continue on their trek without any influence of study administrators. On their ascent from Pheriche, some subjects stopped overnight at a lodge at 4595 m (Thukla) for one night, but all were expected to arrive at 4937 m (Lobuje) for data collection (rate of ascent from Pheriche, Lake Louise 
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Questionnaire score, symptoms of other acute illness, pulse oximetry, and side effects). The study was complete at this point and the data were used to identify participants with acute illness, who could then be treated and/or evacuated as necessary. The capsules were taken for 2 to 3 days in total before the final evaluation in Lobuje.
Analysis
Likelihood ratio tests or Fisher's exact test were used to compare categorical variables.
T-tests were used to compare means of continuous variables, and in all cases p values of less than 0.05 were considered significant.
RESULTS
Of the 197 participants enrolled in the study, 155 completed the study questionnaire at Lobuje (4937 m), with 42 lost to follow-up. All persons whose data were collected at Lobuje were analyzed in the group to which they were assigned originally. For those lost to follow-up, few data are available; however, they were spread almost evenly between the treatment and placebo groups (22 and 20 respectively, p 5 0.99) and were an equal percentage of their respective cohorts (21.3%). At Pheriche the groups were well matched (Table 1) , including those lost to follow-up, and this was considered evidence of appropriate blinding. The outcome profile of subjects who completed the study (n 5 155) is summarized in Table 2 . Analysis for the primary outcome variables revealed that in the treatment group there was a statistically significant reduction in incidence of AMS. Prophylaxis with acetazolamide conferred a 50.6% relative risk reduction, and the number needed to treat in order to prevent one instance of AMS was 8. There were 30% in the placebo group (6 of 20) versus 0% in the acetazolamide group (0 of 9) that experienced a more severe degree of AMS as defined by a Lake Louise Questionnaire score of 5 or greater (p 5 0.14). Several secondary outcome measures in Tables 2 through 4 were associated with statistically significant findings favoring the treatment group, including the presence of headache, final oxygen saturation at Lobuje, and the absolute change in oxygen saturation. Subjects in the treatment group were more likely to miss taking capsules and to experience paresthesias. Furthermore, subjects with paresthesias were more likely to miss taking study capsules: 8 of 39 subjects with paresthesias (20.5%) versus 9 of 116 subjects without paresthesias (7.8%, p 5 0.04). There was no significant difference between groups in the incidence of nonaltitude-related illness, after arriving at Lobuje. There were no cases of HACE or HAPE in either study group, and no identifiable cases of allergic reaction to acetazolamide.
DISCUSSION
Key findings of the study
Acetazolamide 125 mg twice daily was statistically effective in (1) halving the incidence of AMS, (2) decreasing the incidence of high altitude headache, and (3) improving oxygenation. The strong trend of reduced severity of illness in the treatment group probably does not reach statistical significance, because the numbers were not large enough to effectively substantiate the effect. However, the treatment effect of 50% reduction in AMS was similar to that found in other studies, and the treatment group exhibited classic features consistent with a robust clinical effect due to acetazolamide therapy (improved oxygenation and the presence of paresthesias) (Hackett et al., 1976) . Furthermore, one other indicator suggests that acetazolamide may have been even more efficacious than the study was able to show: The treatment group also had a greater degree of medication noncompliance as measured by missed capsules; had they taken all their medications they may have fared even better. The higher rate of paresthesias in the treatment group compared to placebo was expected and is probably related to the overall rate of missed capsules. This association most likely represents medication noncompliance as a result of the bothersome side effect of the paresthesias associated with acetazolamide. The overall rate of AMS in this study population was 18.7%, a lower value than that found in previous studies (Hackett et al., 1976) . Five points are noteworthy. First, since the vast majority of trekkers do not take acetazolamide as a matter of course, the true incidence of AMS is most likely closer to the rate of 24.7% found in the placebo group.
Second, a psychobehavioral cause may be found in the fact that the subjects were recruited at Pheriche after the daily Himalayan Rescue Association informational sessions on altitude sickness, possibly selecting for a more conservative group that were aware of the health risks of altitude and methods of risk reduction. Third, we sampled on the evening of the arrival to Lobuje instead of on the next day when the rates may have been higher. Fourth, since we did not enroll people at Pheriche who had AMS, this certainly influenced the incidence of AMS higher up at Lobuje. Finally, it is true that in recent years the overall incidence of AMS has declined in trekkers who are assessed at Pheriche on their way up (Basnyat et al., 1999; Dubowitz and Miller, 2001) .
Limitations of the study
First, a significant number of participants (21%) were lost to follow-up, and the outcome among these subjects may have affected the significance of our findings. Three points minimize this difficulty: (1) subjects in either group were equally likely to drop out of the study, (2) this degree of attrition is consistent with previous studies, and (3) this degree of attrition is not unexpected in a wilderness setting, with no incentive for subjects to follow up at the ren- dezvous point in Lobuje (Hackett et al., 1976; Murdoch, 1995) . Another limitation of this study is that, with the complaint of paresthesias that is typical for acetazolamide usage, blinding may have been compromised both for the subject and the investigator. However, the method of blinding minimized the impact of this specific difficulty. Finally, the choice of starting point of the study is unusually high since many subjects will suffer from AMS below this altitude, and hence it does make comparison with other studies difficult. However, from our previous anecdotal experience we knew that many people become ill in Lobuje with AMS as compared with Pheriche or any other part of this Everest trek and, in addition, the "logistics" of this sector were very attractive for us. However, we would submit that, if anything, this study showed that even these "hardy" individuals were protected from AMS, which is in keeping with the efficacy of lowdose acetazolamide.
CONCLUSIONS
Acetazolamide 125 mg twice daily was significantly efficacious in decreasing the incidence of AMS in this Himalayan trekking population. The results of this study thus clearly refute Dumont's conclusion that acetazolamide 750 mg is the minimum prophylactic dose. We believe these results are generalizable to many trekking scenarios because of the number and variety of participants involved. Further research with acetazolamide (i.e., an RCT with different acetazolamide dosing arms) to find the optimal balance of efficacy versus side effects would be a significant next step to build on these findings.
